Australia's most trusted
source of pharma news
Sunday, 01 June 2025
Posted 16 May 2025 PM
The very quiet listing of a major new Novartis therapy that has been at the heart of much controversy was our top story this week.
It marked the latest twist in the unusual road to reimbursement for radiogland Pluvicto which will be funded on the MBS for prostate cancer from July this year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.